Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Sumatriptan

Generic name
Sumatriptan
Brand name
ATC Code
N02CC01

Pharmacokinetics in children

5-17 years:
T½ = 1.4-2 hours

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Migraine attach: acute treatment during the headache phase; cluster headache
  • Nasal
    • 6 years up to 18 years and < 40 kg
      • 10 mg/dose, once only (= 1 puff of 10 mg in 1 nostril). Max: 20 mg/day.

      • If the initial treatment has no effect, do not give a second dose for the same episode. If there is a response, the dose may be repeated after at least 2 hours have passed since the previous administration.

    • 6 years up to 18 years and ≥ 40 kg
      • 20 mg/dose, once only (= 2 puffs of 10 mg or 1 puff of 20 mg in 1 nostril). Max: 40 mg/day.

      • If the initial treatment has no effect, do not give a second dose for the same episode. If there is a response, the dose may be repeated after at least 2 hours have passed since the previous administration.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Severe side effects such as myocardial infarction, CVA, loss of visibility and mortality have been reported in oral, nasal and subcutaneous administration. The incidence has not yet been determined.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Selective serotonin (5HT1) agonists
N02CC04
N02CC03
Other antimigraine preparations
N02CX01

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Christensen ML, et al, Pharmacokinetics of sumatriptan nasal spray in adolescents, J Clin Pharmacol, 2003, Jul;43(7), 721-6
  2. Christensen ML, et al, Pharmacokinetics of sumatriptan nasal spray in children, J Clin Pharmacol, 2004, Apr;44(4), 359-67
  3. Ueberall MA, et al, Intranasal sumatriptan for the acute treatment of migraine in children, Neurology, 1999, Apr 22;52(7), 1507-10
  4. Hershey AD, et al, Effectiveness of nasal sumatriptan in 5- to 12-year-old children, Headache, 2001, Jul-Aug;41(7), 693-7
  5. Winner P, et al, A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents, Pediatrics, 2000, Nov;106(5), 989-97
  6. Ahonen K, et al, Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial, Neurology, 2004, Mar 23;62(6), 883-7
  7. Rothner AD, et al, One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study, Clin Ther, 2000, Dec;22(12), 1533-46
  8. Hamalainen ML, et al, Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?, Neurology, 1997, Apr;48(4), 1100-3

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes